As Product Development Partnerships (PDPs) dedicated to the discovery, development and delivery of new global health tools, we applaud the official la...
TB Alliance, an international non-profit organization which develops better, faster-acting, and affordable TB drugs, has announced that it has granted...
Over the past year, the pursuit of new TB drugs has seen incredible progress. Positive results of first regimen trial testing PaMZ, the approval of be...
In spite of an estimated 500,000 new annual cases of children with tuberculosis (TB), there are no appropriate medicines for them, UNITAID and the TB ...
TB Alliance, a not-for-profit organization with the mission of developing better, faster-acting, and affordable TB treatments, announces the election ...
TB Alliance announces new leadership of its Stakeholders Association (SHA), an advisory group comprised of member organizations that share a clear int...
TB Alliance, a not-for-profit organization with the mission of developing new, improved, and affordable TB treatments, announces the election of Karl ...
The phase 2b clinical trial of the TB vaccine candidate MVA85A is historic, the first efficacy study of a novel BCG booster tuberculosis vaccine in in...
Pyrazinamide (PZA) is an incredibly important sterilizing agent in the treatment of tuberculosis and is considered responsible for reducing the durati...
The Global Alliance for TB Drug Development (TB Alliance) is pleased to announce the appointment of Dr. Carlos Morel to Chairman of its Board of Direc...
Press Contact: press@tballiance.org
Falling Short: Ensuring Access to Simple, Safe and Effective First-Line Medicines for Tuberculosis
New TB Regimens: What Countries Want
Pathway to Patients
Policy on the Compassionate / Emergency Use of Experimental TB Alliance Drugs